Conference Proceedings

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

B Burtness, KJ Harrington, R Greil, D Soulieres, M Tahara, G De Castro, A Psyrri, N Baste Rotllan, PC Neupane, A Bratland, T Fuereder, BGM Hughes, R Mesia, N Ngamphaiboon, T Rordorf, WZ Wan Ishak, A Roy, J Cheng, F Jin, D Rischin

Annals of Oncology | OXFORD UNIV PRESS | Published : 2018

Grants

Funding Acknowledgements

Merck & Co., Inc.